海通证券股份有限公司关于 上海君实生物医药科技股份有限公司 2022 年度向特定对象发行 A 股股票 持续督导保荐总结报告书 | 保荐机构名称： | 海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z22531000 | 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导性陈 述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监会"） 对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办法》 的有关规定采取的监管措施。 1 二、保荐机构基本情况 经中国证券监督管理委员会《关于同意上海君实生物医药科技股份有限公司向 特定对象发行股票注册的批复》（证监许可[2022]2616 号）批复，上海君实生物医 药科技股份有限公司（以下简称"上市公司"、"公司"或"发行人"） 向特定对象发行 股票（以下简称"本次证券发行"），每股面值人民币 1 元，每股发行价格人民币 53.95 元，募集资金总额为人民币 377,650.00 ...

Group 1 - The core viewpoint of the news is that Chengquan Capital has conducted research on Junshi Biosciences, highlighting the company's progress in drug development, including various monoclonal antibodies and bispecific antibodies [1] - Junshi Biosciences introduced its JS207 bispecific antibody, which combines anti-PD-1 and anti-VEGF properties, currently undergoing clinical trials for multiple cancers [1] - The JS107 monoclonal antibody is in I/II phase clinical trials, with plans to initiate III phase trials in 2025 [1] - The sales of Toripalimab are expected to grow by 66% in 2024 due to new indications being approved and the increase in indications covered by medical insurance [1] - Tifcemalimab is undergoing two III phase registration clinical studies targeting limited-stage small cell lung cancer and classical Hodgkin lymphoma [1] - The anti-PCSK9 monoclonal antibody, Angrezi, has received NMPA approval for market launch, while the anti-IL-17 monoclonal antibody, JS005, is in III phase registration clinical research [1] Group 2 - Chengquan Capital, established in July 2015, has a registered capital of 50 million yuan and was founded by Hu Jiguang, a notable figure in the asset management industry [2] - The investment research team at Chengquan Capital consists of experienced professionals from leading securities firms and influential research institutions in China, demonstrating strong market sensitivity and risk control capabilities [2] - The company emphasizes a client-centered approach, aiming for wealth preservation and growth for clients, employees, and shareholders, aspiring to be a respected and influential investment institution in the domestic capital market [2]

Core Viewpoint - Junshi Biosciences (SH688180) reported a continued narrowing of net losses in its 2024 annual report, with significant revenue growth driven by its core product, Toripalimab [1][2] Financial Performance - In 2024, Junshi Biosciences achieved revenue of 1.948 billion yuan, a year-on-year increase of 29.67%, while the net loss was 1.281 billion yuan, representing a 43.89% reduction in losses compared to the previous year [1][2] - The company has now recorded two consecutive years of revenue growth and a reduction in net losses since 2023 [1] Product Performance - Toripalimab generated sales of 1.501 billion yuan in 2023, a 66% increase year-on-year, accounting for 77% of the company's total revenue [1][2] - The product has received approvals for multiple new indications, including late-stage triple-negative breast cancer, late-stage renal cell carcinoma, and extensive small cell lung cancer, with a total of 11 approved indications in mainland China [2][3] Sales and Market Strategy - The sales team has improved efficiency, with a significant increase in per capita sales efficiency and a reduction in sales expense ratio in 2024, which is expected to decrease further in 2025 and 2026 [1][4] - Toripalimab is the only PD-1 monoclonal antibody covered by national health insurance for specific indications, contributing 25% of revenue from lung cancer indications [3] International Expansion - The company anticipates rapid growth in overseas revenue for Toripalimab, having officially launched in the U.S. market in January 2024 and received approvals in over 30 countries and regions [4] R&D Pipeline - The Tifcemalimab project, an anti-tumor anti-BTLA monoclonal antibody, is in phase III clinical trials and is the second-largest investment project for Junshi Biosciences, with expected mid-term data readouts between 2026 and the first half of 2027 [5]

Core Insights - Junshi Biosciences (1877.HK, 688180.SH) reported a revenue of 1.948 billion yuan for 2024, marking a year-on-year increase of 29.67% driven by the growth in commercialized drug sales [1] - The company's net loss narrowed to 1.281 billion yuan, a reduction of over 1 billion yuan compared to the previous year, indicating improved financial health [1] - Junshi Biosciences has a robust pipeline with nearly 30 drug candidates in clinical trials and over 20 in preclinical development [1] Revenue and Financial Performance - The revenue growth is attributed to the strong performance of the core product, Toripalimab, which achieved sales of 1.501 billion yuan in the domestic market, a significant increase of approximately 66% year-on-year [1] - The company’s cash and financial assets totaled about 2.933 billion yuan by the end of 2024, reflecting a solid financial reserve [1] Product Development and Market Expansion - Toripalimab's rapid growth is supported by the efficient advancement of research and registration, with new indications approved in recent years, including late-stage triple-negative breast cancer and advanced renal cell carcinoma [2] - The drug has been included in the national medical insurance catalog for its first ten indications, providing a competitive edge in market promotion [2] - Junshi Biosciences has expanded its product matrix with the addition of its fifth commercialized product, Angrexis, broadening its therapeutic areas [3] Global Commercialization Efforts - Toripalimab is the first domestic PD-1 drug to successfully enter international markets, with FDA approval and sales commencing in the U.S. in January 2024 [4] - The drug has been approved in over 35 countries and regions, including the U.S., EU, and Australia, and is the only drug recommended for certain cancer treatments in these markets [4][5] Pipeline and Future Growth - The company is advancing several high-potential pipeline products, including anti-BTLA monoclonal antibody tifcemalimab and anti-IL-17A monoclonal antibody JS005, which are expected to contribute to future growth [6] - The PD-1/VEGF dual antibody JS207 is also in development, aiming to enhance anti-tumor effects by targeting both PD-1 and VEGF [6]

海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 2024 年度持续督导现场检查报告 （一）保荐机构 海通证券股份有限公司 （二）保荐代表人 上海证券交易所： 经中国证券监督管理委员会《关于同意上海君实生物医药科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]940 号）批复，上海君实生 物医药科技股份有限公司（以下简称"君实生物"、"上市公司"、"公司"）首次 公开发行股票 8,713.00 万股，每股面值人民币 1 元，每股发行价格人民币 55.50 元，募集资金总额为人民币 4,835,715,000.00 元，扣除发行费用后，实际募集资 金净额为人民币 4,496,978,326.73 元。上述资金已全部到位，容诚会计师事务所 （特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验，并于 2020 年 7 月 8 日出具了容诚验字[2020]230Z0103 号《验资报告》。首次公开发行 证券已于 2020 年 7 月 15 日在上海证券交易所上市。海通证券股份有限公司（以 下简称"保荐机构"或"海通证券"）担任其持续督导保荐机构。 经中国证券监督管理委员会《关于同 ...

Core Insights - In 2024, Junshi Biosciences' PD-1 monoclonal antibody Tuoyi achieved domestic sales revenue of 1.501 billion yuan, representing a year-on-year growth of approximately 66% [1] - The company reported a significant narrowing of net profit loss, with a total revenue of 1.948 billion yuan, up 29.67% year-on-year, and a net profit loss of 1.281 billion yuan, a reduction of about 44% compared to the previous year [1] - Junshi Biosciences has four commercialized drugs, including Tuoyi, with 11 approved indications in China, including treatments for kidney cancer and triple-negative breast cancer, making it the first immunotherapy approved in these areas [1] Financial Performance - The company’s total revenue for 2024 was 1.948 billion yuan, a 29.67% increase year-on-year [1] - The net profit loss for the year was 1.281 billion yuan, which is a 44% reduction compared to the previous year [1] - Sales expenses for drugs were 985 million yuan, a 16.6% increase, but lower than the growth rate of sales revenue [2] Research and Development - R&D expenses decreased to 1.275 billion yuan, down 34.18% year-on-year, attributed to the completion of multiple clinical trials for drugs like Tuoyi and Junshida [2] - The company has nearly 30 drug candidates in clinical trials and over 20 in preclinical development [2] - Junshi Biosciences aims to focus resources on more promising R&D projects and is implementing a "quality improvement and efficiency return" action plan [2] Market Expansion - Tuoyi is expanding into international markets, having received approvals in the US, EU, India, UK, Jordan, Australia, and Singapore, although overseas sales figures have not been disclosed [2] - The company plans to selectively seek overseas strategic partners to enhance the commercialization potential of its drugs and diversify revenue sources [2]

Core Insights - Junshi Biosciences (SH688180) reported a revenue of 1.948 billion yuan for 2024, representing a year-on-year growth of 29.67% [1] - The company recorded a net loss of 1.281 billion yuan, which is a 43.90% reduction compared to the previous year [1] - The increase in revenue is attributed to the growth in sales of commercialized drugs [1] Revenue and Profitability - The main commercialized products include Toripalimab injection (brand name: Tuoyi), Adalimumab injection (brand name: Junmaikang), Dexamethasone Hydrochloride tablets (brand name: Mindewi), and Ongericimab injection (brand name: Junshida) [1] - Toripalimab remains the revenue driver, achieving domestic sales of 1.501 billion yuan in 2024, a year-on-year increase of approximately 66% [1] - The growth in Toripalimab's sales is linked to the approval of four new indications in 2024, bringing the total to 11 indications [1] Research and Development - The R&D expenses for Junshi Biosciences in 2024 were 1.275 billion yuan, a decrease of 34.18% year-on-year [2] - The number of R&D personnel decreased from 736 to 620 [2] Strategic Focus - The company is implementing a "quality improvement and efficiency enhancement" action plan to strengthen cost control and improve sales efficiency [1] - Resources are being concentrated on more promising R&D projects to further reduce losses [1]

上海君实生物医药科技股份有限公司 关于设立董事会合规委员会及制定 《董事会合规委员会工作细则》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688180 证券简称：君实生物 公告编号：临 2025-018 董事会 2025 年 3 月 28 日 特此公告。 上海君实生物医药科技股份有限公司 上海君实生物医药科技股份有限公司（以下简称"公司"）于2025年3月27 日召开第四届董事会第七次会议，审议通过了《关于设立董事会合规委员会及制 定<董事会合规委员会工作细则>的议案》，现将具体情况公告如下： 为推动公司全面构建合规管理体系，加强合规建设，有效防控合规风险，促 进公司依法合规经营管理，保障公司持续稳定健康发展，公司在董事会下增设合 规委员会，由独立非执行董事鲁琨女士、郦仲贤先生、张淳先生担任第四届董事 会合规委员会委员，由鲁琨女士担任主任委员，任期自公司第四届董事会第七次 会议审议通过之日起至公司第四届董事会任期届满之日止。 为规范董事会合规委员会的职责权限、决策程序等事项，公司制定了《上海 君实生物 ...

董事会 2025 年 3 月 27 日 经核查公司在任独立非执行董事张淳、冯晓源、杨悦、郦仲贤及鲁琨的 兼职、任职情况以及其签署的独立性自查情况报告，上述人员除在公司担任 独立非执行董事、董事会专门委员会委员外，不存在在公司任职以及在公司 主要股东单位任职的情形，与公司以及主要股东之间不存在利害关系、重大 业务往来或其他可能妨碍其独立性的关系。因此，董事会认为公司独立非执 行董事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》中对独立非执行董事独立性的相关 要求。 上海君实生物医药科技股份有限公司 上海君实生物医药科技股份有限公司 董事会 2024 年度对独立非执行董事独立性 自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等相关要求，上海君实生物医药科技股份有限公司（以下简称"公司"） 董事会，就公司在任独立非执行董事的独立性情况进行评估并出具如下专 项意见： ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》和《上海君实生物医药科技股份 有限公司章程》（以下简称"《公司章程》"）《上海君实生物医药科技股份有 限公司董事会审计委员会工作细则》等规定和要求，上海君实生物医药科技股份 有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职 守，认真履职。现将公司董事会审计委员会对容诚会计师事务所（特殊普通合伙） （以下简称"容诚会计师事务所"）2024 年度履职情况评估及履行监督职责的情 况汇报如下： 一、2024 年年审会计师事务所基本情况 上海君实生物医药科技股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情 况评估及履行监督职责情况的报告 （一）资质条件 1、基本信息 容诚会计师事务所由原华普天健会计师事务所（特殊普通合伙）更名而来， 初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通合伙企业，是国内 最早获准从事证券服务业务的会计师事务所之一，长期从事证券服务业务。 ...